1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24284
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFountzilas, G.en
dc.contributor.authorFragkoulidi, A.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorNikolaidou, M.en
dc.contributor.authorBobos, M.en
dc.contributor.authorCalderaro, J.en
dc.contributor.authorAndreiuolo, F.en
dc.contributor.authorMarselos, M.en
dc.date.accessioned2015-11-24T19:39:58Z-
dc.date.available2015-11-24T19:39:58Z-
dc.identifier.issn1432-0843-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24284-
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAngiogenesis Inhibitors/adverse effects/pharmacokinetics/*therapeutic useen
dc.subjectAnorexia/chemically induceden
dc.subjectArea Under Curveen
dc.subjectCarcinoma, Squamous Cell/*drug therapy/metabolism/pathologyen
dc.subjectDrug Administration Scheduleen
dc.subjectFatigue/chemically induceden
dc.subjectFemaleen
dc.subjectHead and Neck Neoplasms/*drug therapy/metabolism/pathologyen
dc.subjectHumansen
dc.subjectHypoxia-Inducible Factor 1, alpha Subunit/metabolismen
dc.subjectImmunohistochemistryen
dc.subjectIndoles/blood/pharmacokinetics/*therapeutic useen
dc.subjectMaleen
dc.subjectMetabolic Clearance Rateen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Metastasisen
dc.subjectNeoplasm Recurrence, Localen
dc.subjectPyrroles/blood/pharmacokinetics/*therapeutic useen
dc.subjectSurvival Analysisen
dc.subjectThrombocytopenia/chemically induceden
dc.subjectTreatment Outcomeen
dc.subjectVascular Endothelial Growth Factor A/metabolismen
dc.titleA phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck canceren
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s00280-009-1070-1-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19655144-
heal.identifier.secondaryhttp://www.springerlink.com/content/37426q115253870v/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2010-
heal.abstractPURPOSE: Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) bear a grave prognosis. There are unmet needs for the development of novel agents for this incurable disease. Angiogenesis is an important biological process in SCCHN. We, therefore, evaluated the activity and safety of sunitinib, an oral tyrosine kinase inhibitor that targets multiple receptors, in patients with RM-SCCHN. PATIENTS AND METHODS: Seventeen patients were treated with sunitinib 50 mg per day administrated in 4-week cycles followed by a rest period of 2 weeks. Sunitinib and SU012662 plasma levels were determined based on a validated liquid chromatography-tandem mass spectrometry method and pharmacokinetic data were fitted in a non-compartmental analysis. RESULTS: Totally, 28 6-week cycles of treatment with sunitinib were administered (median, 2 cycles). Only three patients demonstrated stabilization of the disease; therefore, the study had to be terminated prematurely due to futility. Grade 3 toxicities, apart from fatigue, were infrequent. Other frequently reported side effects were skin discoloration, neutropenia, and thrombocytopenia. Ten various bleeding complications were reported in seven patients. Mean maximum concentrations (C(max)) were reached during the first day of treatment for sunitinib at 38.98 (+ or - 22.66) ng/ml and for SU012662 at 11.12 (+ or - 24.57) ng/ml. Our results showed that SU012662 has a longer half-life and a larger volume of distribution than the parent drug sunitinib. None of the biological markers tested was of any prognostic value. CONCLUSIONS: According to our findings, sunitinib monotherapy was not proven active in RM-SCCHN, and no further development of the drug in this indication is warranted.en
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Fountzilas-2010-A phase II study of.pdf638.92 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons